NRSNFinancing•prnewswire•
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
Sentiment:Positive (65)
Summary
(NASDAQ:NRSN) Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by prnewswire